Purchase this article with an account.
Simon Kaja, Anna A Shah, Shamim Ahmed Haji, Krishna Patel, Yuliya Naumchuk, Nancy Kunjukunju, Nelson R Sabates, Michael A Cassell, Abraham Poulose, Peter Koulen; Serum Nampt/PBEF/visfatin levels correlate with incidence of retinal vein occlusions.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1717.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Nampt (nicotinamide phosphoribosyltransferase) / PBEF (Pre B-Cell colony enhancing factor) / visfatin is a critical rate-limiting enzyme in the nicotinamide adenine dinucleotide pathway critical for cellular energy metabolism. Furthermore, Nampt/PBEF/visfatin has been shown to possess pro-inflammatory activity as a cytokine and participate in the regulation of blood glucose levels. Retinal vascular occlusions (RVOs) are disease conditions characterized by pronounced ischemia and metabolic energy deficits. Currently, there is currently no intervention that has emerged as the standard of care for RVOs. Given the critical role of Nampt/PBEF/visfatin in energy metabolism, and the increased energy demand during traumatic cellular events such as ischemia, we hypothesized Nampt/PBEF/visfatin serum levels may potentially serve as a biomarker or predictor of treatment outcome for RVOs.
We quantified Nampt/PBEF/visfatin in serum obtained from healthy controls and patients, who presented with RVO, using a commercially available enzyme-linked immunosorbent assay.
Nampt/PBEF/visfatin serum levels were 79% lower in patients with a history of RVO compared with healthy volunteers (P<0.05). There was no statistically significant difference among types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemi retinal vein occlusions (n=3) and central retinal artery occlusions (n=3; P=0.69).
Low Nampt/PBEF/visfatin serum levels might serve as a potential biomarker for increased risk for RVO and Nampt/PBEF/visfatin deficiency may contribute to the etiology of RVO. Nampt/PBEF/visfatin represents a potentially novel, druggable target that can be exploited in future therapy development efforts for RVOs and reduce the long-term complications associated with the condition, such as macular edema, macular ischemia, neovascularization and irreparable loss of vision.
This PDF is available to Subscribers Only